This webinar introduces the use of the human immunodeficiency virus (HIV) in the huNOG mouse for better preclinical drug candidate selection and combotherapy profiling. HIV is a human specific virus targeting human CD4 positive circulating lymphocytes. During the past 10 years, the development of the reconstitution of a fully functional human immune system in NOG mice (huNOG) has provided the opportunity to setup HIV huNOG mouse models.
After 15 weeks of reconstitution, huNOG mice can be infected intraperitoneally with HIV, and 3-4 weeks later, in vivo profiling of new anti-HIV drug candidates can be initiated. Typically, we assess efficacy, resistance, rebound, latency and combotherapy, as HIV infection leads to a stable and elevated viral load in the blood. Conventional HAART therapy for 3 weeks decreases by 95% the circulating viral load, and treatment cessation induces a rebound as observed in HIV/AIDS patients. Different HIV strains can be used for the successful infection of huNOG. Cytolytic and cytopathic effects have been studied on hu-CD4 positive lymphocytes from HIV mice.
In addition, we will report on various routes of infection and the development of a vaginal infection protocol which allow the profiling of anti-HIV vaginal gels. HuNOG models have an important role in all aspects of HIV research including, but not restricted to, the characterization of successful medical anti-HIV prevention strategies, the evaluation of new treatment regimens, and the evaluation of novel HIV eradication strategies.
Dr. Patrick Nef is Chief Executive Officer and Founder at TransCure bioServices SAS. He holds a PhD in Molecular Neurobiology from the University of Geneva, Switzerland. He has more than 30 years of experience as Assistant Professor at the Univ. of Geneva, Vice-Director at F. Hoffmann-La Roche, ltd, Basel and CSO, CBO and CEO for several biotechnology driven companies. In 2012, he founded TransCure bioServices SAS. Patrick Nef has published more than 50 peer-reviewed publications and patents in the field of sensory olfaction, learning and memory, and calcium sensors.
Dr. Sebastien Tabruyn is Chief Scientific Officer at TransCure bioServices SAS. He holds a PhD in Molecular Biology from the University of Liege (Belgium). After 10 years of experience as project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn has published 30 peer-reviewed publications in the fields of oncology, angiogenesis and inflammation.
Key Learning Points:
How humanized immune system mice can be used to model HIV
How humanized mice can be infected with HIV, including use of different routes of infection and HIV strains
How HIV infection can be monitored in huNOG mice
How anti-retroviral therapy suppresses viral load in HIV-infected humanized mice
How drug candidates can be profiled in the humanized mouse model of HIV